Table 2.
Genotypic and allelic distribution of the –2518 CCL2 (A/G) and CCR2 polymorphisms in Spanish patients with chronic hepatitis C (CHC) and healthy controls
| Genotypes | CHC n = 284 (%) | F0-F2 n = 202 (%) | F3-F4 n = 82 (%) | SR n = 101 (%) | NSR n = 98 (%) | Healthy controls n = 193 (%) |
| -2518 CCL2 AA | 168 (59.2) | 123 (60.9) | 45 (54.0) | 64 (63.4) | 55 (56.1) | 119 (61.6) |
| -2518 CCL2 AG + GG | 116 (40.9) | 79 (39.1) | 37 (46.0) | 37 (36.6) | 43 (43.9) | 74 (38.4) |
| 190 CCR2 GG | 205 (72.2) | 146 (72.3) | 59 (72.0) | 72 (71.3) | 74 (75.5) | 156 (80.8%) |
| 190 CCR2 AG + AA | 79 (27.8) | 56 (27.7) | 23 (28.0) | 29 (28.7) | 24 (24.5) | 37 (19.1%) |
| CCR2 rs3138042 AA | 134 (47.2) | 93 (46.0) | 41 (50.0) | 48 (47.5) | 46 (46.9) | 102 (52.9) |
| CCR2 rs3138042 AG | 124 (43.7) | 91 (45.1) | 33 (40.2) | 42 (41.6) | 45 (45.9) | 72 (37.3) |
| CCR2 rs3138042 GG | 26 (9.2) | 18 (8.9) | 8 (9.8) | 11 (10.9) | 7 (6.9) | 19 (9.8) |
F0-F2 = no fibrosis-mild fibrosis, F3-F4 = severe fibrosis-cirrhosis. SR: sustained response; NSR: no sustained response.